Companies:
50,299
Total Market Cap:
142399139536346.83
Global Rank
#20900
Country Rank
#147
Market Cap
184.54 M
Price
9.25
Change (%)
3.89%
Volume
89,947
Newron Pharmaceuticals S.p.A.'s latest marketcap:
184.54 M
As of 08/09/2025, Newron Pharmaceuticals S.p.A.'s market capitalization has reached $184.54 M. According to our data, Newron Pharmaceuticals S.p.A. is the 20900th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 184.54 M |
| Revenue (ttm) | 59.67 M |
| Net Income (ttm) | 18.4 M |
| Shares Out | 19.96 M |
| EPS (ttm) | 0.89 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 09/16/2025 |
Market Cap Chart
Data Updated: 08/09/2025
Newron Pharmaceuticals S.p.A.'s yearly market capitalization.
Newron Pharmaceuticals S.p.A. has seen its market value drop from ₣341.71 M to ₣149.11 M since 2014, representing a total decrease of 56.36% and an annual compound decline rate (CAGR) of 7.52%.
| Date | Market Cap(₣) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 08/09/2025 | ₣149.11 M | $184.54 M | -19.88% | 20900 |
| 12/30/2024 | ₣174.16 M | $191.76 M | 97.16% | 19238 |
| 12/29/2023 | ₣88.33 M | $104.92 M | 219.35% | 22721 |
| 12/30/2022 | ₣27.66 M | $29.9 M | -4.32% | 30237 |
| 12/30/2021 | ₣28.91 M | $31.69 M | -24.65% | 30283 |
| 12/30/2020 | ₣38.37 M | $43.34 M | -66.14% | 25522 |
| 12/30/2019 | ₣113.32 M | $116.96 M | 13.19% | 17310 |
| 12/28/2018 | ₣100.11 M | $101.92 M | -51.62% | 17163 |
| 12/29/2017 | ₣206.91 M | $212.07 M | -34.9% | 14341 |
| 12/30/2016 | ₣317.83 M | $311.5 M | -12.68% | 11075 |
Company Profile
About Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company specializing in the development of innovative therapies for central nervous system (CNS) disorders and pain management. Headquartered in Bresso, Italy, the company operates in Italy and the United States.
Key Products
- Xadago (safinamide): A treatment for Parkinson’s disease, available in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the UAE, Japan, and South Korea.
Product Pipeline
- Evenamide: An add-on therapy for schizophrenia and treatment-resistant schizophrenia, currently in Phase III clinical trials.
- Ralfinamide: A treatment for rare neuropathic pain indications.
Strategic Partnerships
- Collaboration with Zambon for the commercialization of safinamide.
- License agreement with Meiji Seika Pharma Co., Ltd. for the research, development, manufacturing, and marketing of safinamide.
Founded: 1999
Frequently Asked Questions
-
What is Newron Pharmaceuticals S.p.A.'s (SWX-NWRN) current market cap?As of 08/09/2025, Newron Pharmaceuticals S.p.A. (including the parent company, if applicable) has an estimated market capitalization of $184.54 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Newron Pharmaceuticals S.p.A. (SWX-NWRN) rank globally by market cap?Newron Pharmaceuticals S.p.A. global market capitalization ranking is approximately 20900 as of 08/09/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.